Advances in Radiation Oncology最新文献

{"title":"Sexual Toxicity After Chemoradiation for Anal Cancer Among Men Who Have Sex With Men: A Mixed-Methods Analysis","authors":"Beck O. Gold BS ,&nbsp;Angie Arzola PA-C ,&nbsp;Benjamin R. Schrank MD, PhD ,&nbsp;Van K. Morris MD ,&nbsp;Christophe Marques MD, PhD ,&nbsp;Jaime Gilliland MA ,&nbsp;Thomas M. Atkinson PhD ,&nbsp;Emma B. Holliday MD","doi":"10.1016/j.adro.2025.101983","DOIUrl":"10.1016/j.adro.2025.101983","url":null,"abstract":"<div><h3>Purpose</h3><div>Chemoradiation (CRT) is the standard of treatment for localized anal squamous cell carcinoma (SCCA). Although cure rates are high, acute and late toxicities are common. There are increasing published data regarding vaginal stenosis and erectile dysfunction; however, the nature and impact of holistic sexual dysfunction after pelvic radiation, particularly among men who have sex with men (MSM), remains poorly characterized. This study aimed to: (1) explore patient-reported sexual health outcomes among MSM as measured by existing patient-reported outcome tools, and (2) assess the applicability of these existing tools for this population.</div></div><div><h3>Methods and Materials</h3><div>MSM who are at least 6 months out from completion of CRT for SCCA were recruited via fliers and online platforms. Participants completed a sexual patient-reported outcome questionnaire that included previously validated instruments assessing symptom burden, sexual function and satisfaction, erectile function, and pain with receptive anal intercourse. This was followed by a semistructured interview. Descriptive statistics were used to report demographics and survey data. McNemar’s test compared sexual activities pre- and post-CRT. Interview data were thematically analyzed using inductive coding.</div></div><div><h3>Results</h3><div>Of the 23 participants who completed the questionnaire, 19 completed an interview. The median (IQR) time since completing CRT was 3.1 (1.2-4.8) years. Approximately half (N = 11) had moderate to severe erectile dysfunction (median International Index of Erectile Function [IIEF-5] = 12; IQR, 6-20). Since completing treatment, 9 (39.1%) had attempted receptive anal penetration. Of those who had attempted receptive anal penetration, 66.7% experienced pain, and an equal percentage reported moderate-severe distress and interpersonal/relationship difficulty as a result. In general, patients reported participating in fewer sexual activities after CRT. Emergent themes from interviews included the need for patient education, the interplay between other radiation side effects and sexual side effects, and positive reactions to the survey measures.</div></div><div><h3>Conclusions</h3><div>Sexual dysfunction is common among MSM following CRT for SCCA. Erectile dysfunction and/or pain with receptive anal intercourse often lead to distress and interpersonal relationship challenges. Improved patient education and targeted interventions are needed to support sexual function and quality of life in this population.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 3","pages":"Article 101983"},"PeriodicalIF":2.7,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Spatially Fractionated Radiation Therapy Combined With Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Inhibitor in the Treatment of Giant Metastatic Hepatocellular Carcinoma: A Case Report","authors":"Yue Jin MD,&nbsp;Liwen Qian MD,&nbsp;Yanjun Gu MD,&nbsp;Benxing Gu MD,&nbsp;Chong Shen MD,&nbsp;Xiaonan Sun PhD","doi":"10.1016/j.adro.2025.101973","DOIUrl":"10.1016/j.adro.2025.101973","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 3","pages":"Article 101973"},"PeriodicalIF":2.7,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Evaluation of Stereotactic Body Radiation Therapy for Reirradiation of Bone Metastases","authors":"Lubna Hammoudeh MD ,&nbsp;Kee-Young Shin MS ,&nbsp;Lauren Hertan MD ,&nbsp;Monic Krishnan MD ,&nbsp;Alex Spektor MD ,&nbsp;Mai Anh Huynh MD, PhD ,&nbsp;Chloe Fisher BSc ,&nbsp;Tracy Balboni MD","doi":"10.1016/j.adro.2025.101886","DOIUrl":"10.1016/j.adro.2025.101886","url":null,"abstract":"<div><h3>Purpose</h3><div>Bone metastases are a common cause of morbidity among patients with cancer, and radiation therapy (RT) is efficacious for their palliation. However, symptomatic bone metastases can often occur in regions that have received prior RT, limiting doses that can be delivered safely. Stereotactic body radiation therapy (SBRT) enables the delivery of greater doses of RT to the tumor while minimizing reirradiation dose to critical organs at risk.</div></div><div><h3>Methods and Materials</h3><div>In this prospective, multi-institutional phase 2 trial, 45 patients with bone metastasis in a previously irradiated region were treated with SBRT from February 2017 to November 2021. The primary endpoint was local control at 6 months post RT; secondary aims were rates of acute and chronic toxicity, time to local progression, local progression rate, progression-free survival, and overall survival.</div></div><div><h3>Results</h3><div>The median age of participants was 62.6 years, and most were male (75.6%). The most common primary tumor types were as follows: prostate (13/45, 28.9%), lung (8/45, 17.8%), and renal cell (5/45, 11.1%). The majority received reirradiation to a spinal lesion (35/45, 77.7%). The most common dose prescriptions were 30 Gy in 5 fractions (24/45, 53.3%) and 35 Gy in 5 fractions (11/45, 24.4%). At 6 months, 42 of 45 treated sites were locally controlled, whereas 3 had progressed at a median of 3.6 months. The local progression-free rate was 89.9% at 2 years. Overall survival was 52% at 2 years. Acute toxicities occurred in 46.7%, most commonly fatigue, nausea, and pain flare; all were grade 1 or 2. In total, 8.9% of participants experienced chronic toxicities, including vertebral fracture and pain flare, all grade 1 or 2 with no myelopathies.</div></div><div><h3>Conclusions</h3><div>This prospective study of SBRT for reirradiation of bone metastases demonstrated effective local control and reasonable rates of acute and chronic toxicities. Additional research is needed to further ascertain long-term efficacy and treatment-related toxicities.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 1","pages":"Article 101886"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative and Customized 3-Dimensional-Printed Mold Brachytherapy Treatment of Genital Extramammary Paget’s Disease","authors":"Ruben Del Castillo Pacora MD ,&nbsp;Moti R. Paudel PhD ,&nbsp;Mackenzie Smith MSC ,&nbsp;Gerard Morton MD ,&nbsp;Elizabeth Barnes MD ,&nbsp;Mohammad Kazem ,&nbsp;Michael Sidiropoulos MD ,&nbsp;Amandeep S. Taggar MD","doi":"10.1016/j.adro.2025.101969","DOIUrl":"10.1016/j.adro.2025.101969","url":null,"abstract":"<div><h3>Purpose</h3><div>Extramammary Paget’s disease (EMPD) is a rare intraepithelial neoplasm that affects apocrine gland-rich areas of the perineal region. Surgical treatment is the standard of care but is associated with significant morbidity. Nonsurgical options, such as surface mold brachytherapy (SMBT) with custom 3-dimensional (3D)-printed applicators, offer an innovative, organ-preserving alternative. Our aim was to evaluate the efficacy, safety, and cosmetic outcomes of custom 3D-printed SMBT in patients diagnosed with EMPD.</div></div><div><h3>Methods and Materials</h3><div>A retrospective case series involving 9 patients treated for EMPD between November 2019 and April 2023 was included. Patient demographics, clinical characteristics, treatment parameters, and outcomes were analyzed. Primary outcomes included clinical response rates, acute and late toxicities (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5), and patient-reported cosmetic outcomes.</div></div><div><h3>Results</h3><div>All 9 patients (6 men and 3 women) achieved a complete clinical response, with 1 patient experiencing marginal recurrence at 13.6 months posttreatment. Acute grade 3 dermatitis occurred in all patients and resolved, on average, within 54 days (range, 35-72). Late toxicities included hypopigmentation (4 patients) and telangiectasia (3 patients). Cosmetic outcomes were rated as excellent or very good by 89% of patients.</div></div><div><h3>Conclusions</h3><div>This study represents the first report on the use of custom 3D-printed SMBT for EMPD. This technique demonstrates excellent local control, manageable toxicity, and favorable cosmetic outcomes, offering a promising alternative to surgery in this anatomically complex area.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 3","pages":"Article 101969"},"PeriodicalIF":2.7,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145881695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single-Dose Intravenous-Contrast Enhanced 4-Dimensional Computed Tomogram Facilitated Accurate Delineation and Tracking Metastatic Tumor Motion Within a Cardiac Chamber in all Breathing Phases for Cardiac Metastasis-Directed Radiation Therapy","authors":"Whoon Jong Kil MD ,&nbsp;Wyatt Smith CMD ,&nbsp;David Cousins MD ,&nbsp;Eugene Muchnik MD ,&nbsp;Renee Muchnik MD ,&nbsp;Craig Herndon PhD ,&nbsp;Haejin Kang PhD","doi":"10.1016/j.adro.2025.101978","DOIUrl":"10.1016/j.adro.2025.101978","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 4","pages":"Article 101978"},"PeriodicalIF":2.7,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons Learned From an Epic Transformation of a Radiation Oncology Department in Guatemala: Keys to Success","authors":"Edgar Ruiz MD ,&nbsp;Hiram A. Gay MD ,&nbsp;Milton Ixquiac MS ,&nbsp;Angel Velarde MD ,&nbsp;Baozhou Sun PhD ,&nbsp;Jose García-Ramirez MS ,&nbsp;Eric Laugeman MS ,&nbsp;Benjamin Li MD ,&nbsp;Jeff Michalski MD ,&nbsp;Vicky de Falla MD ,&nbsp;Geoff Hugo PhD ,&nbsp;Jacaranda Van Rheenen PhD","doi":"10.1016/j.adro.2025.101928","DOIUrl":"10.1016/j.adro.2025.101928","url":null,"abstract":"<div><h3>Purpose</h3><div>We describe the radical modernization of a radiation oncology department in a developing country, Guatemala, from 2015 to the beginning of 2024. The Instituto de Cancerología y Hospital Dr. Bernardo del Valle S (INCAN) is the only public radiotherapy clinic serving patient referrals from the Ministry of Public Health and Social Assistance program.</div></div><div><h3>Methods and Materials</h3><div>We describe the state of the radiation oncology department in 2015 versus 2024 while chronicling its gradual transformation. This multifaceted collaboration involved academic centers, government agencies, International Atomic Energy Agency (IAEA), industry, and nonprofits and continues to this day. We analyze the infrastructure, staff, radiotherapy equipment, physics equipment, patient careCo-60 decommissioning, and educational initiatives.</div></div><div><h3>Results</h3><div>We graphically illustrate the impact of these changes in treatment delivery time, consults, follow-up visits, CT simulations, new patients treated in each linear accelerator, new patients treated with 2D, 3D, IMRT/VMAT, and superficial techniques, new patients treated with 2D LDR, 2D HDR, or 3D techniques, causes of linear accelerator downtime, and weekly patients on treatment. We provide a figure of the various sequential and parallel steps to modernize a radiation oncology department. We describe the complexities of radioisotope repatriation and safe disposal. We provide a comprehensive table of wisdom pearls regarding project governance, team, education, finances, culture, and language. We also discuss the impact of artificial intelligence in contouring</div></div><div><h3>Conclusion</h3><div>The transformation of the INCAN radiation oncology department in Guatemala is a testimony to many's hard work, vision, and perseverance for the betterment of Guatemalan patients while facing incredible financial hardship. We hope that what we have learned in the past nine years will help others achieve even greater success in a shorter time</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 1","pages":"Article 101928"},"PeriodicalIF":2.7,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impacts of FLASH Radiation Therapy and Conventional Radiation Therapy on the Cognitive Abilities of Mice","authors":"Renke He MD ,&nbsp;Shengqiang Xie MD ,&nbsp;Lehui Du MD ,&nbsp;Wenxuan Li MM ,&nbsp;Jianxin Wang PhD ,&nbsp;Xianhong Liu PhD ,&nbsp;Dai Wu PhD ,&nbsp;Yiwei Yang PhD ,&nbsp;Baolin Qu MD ,&nbsp;Gang Cheng MD ,&nbsp;Jianning Zhang MD","doi":"10.1016/j.adro.2025.101950","DOIUrl":"10.1016/j.adro.2025.101950","url":null,"abstract":"<div><h3>Purpose</h3><div>Preclinical studies have demonstrated that FLASH radiation therapy (RT) delivered at ultrahigh-dose rates exerts a preferential normal tissue-sparing effect. This study aimed to delineate the disparities in delayed cognitive function and biological outcomes of whole-brain irradiation in healthy mice, comparing FLASH-RT with conventional RT (CONV-RT).</div></div><div><h3>Methods and Materials</h3><div>Eighty adult male C57BL/6J mice were divided into 5 groups: Sham, CONV-RT10Gy, CONV-RT20Gy, FLASH-RT10Gy, and FLASH-RT20Gy. Whole-brain irradiation was conducted on mice using a miniaturized x-ray FLASH platform at field-average dose rates of 2 Gy/min for CONV-RT and 213 Gy/s for FLASH-RT. Two months after irradiation, we assessed the mice’s cognitive function and the number of astrocytes and neurons in the hippocampus, then conducted proteomic analyses of their hippocampus.</div></div><div><h3>Results</h3><div>Following the administration of a 20 Gy FLASH-RT dose, the incidence of radiodermatitis was markedly lower than that observed with CONV-RT, accompanied by an improvement in survival rates. Compared with the Sham and FLASH-RT groups, the CONV-RT group exhibited reduced exploration of the open arms in the elevated plus maze, diminished preference for the novel arm in the Y-maze, a lower discrimination index in the novel object recognition test, and prolonged latency to reach the platform in the water maze test. Compared with the FLASH-RT group, the CONV-RT group exhibited an increase in astrocytes and a decrease in neurons in the hippocampus. Proteomic analysis revealed that FLASH-RT may improve the oxidative stress damage caused by CONV-RT.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that FLASH-RT conferred significant advantages over CONV-RT in preserving delayed cognitive function and reducing radiation-induced toxicity in healthy mice. Compared with CONV-RT, FLASH-RT mitigated behavioral deficits across multiple cognitive domains and attenuated hippocampal oxidative stress, highlighting its neuroprotective potential. These findings provided compelling preclinical evidence supporting the therapeutic promise of FLASH-RT as a safer alternative to conventional RT for protecting normal brain function.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 1","pages":"Article 101950"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Survival in Men 80 and Older With Intermediate-Risk Prostate Cancer Who are Treated With Dose-Escalated Radiation and Androgen Deprivation Therapy Versus Dose-Escalated Radiation Alone: A National Cancer Database Analysis","authors":"Timothy P. Dougherty MD ,&nbsp;Mengying Deng MMATH ,&nbsp;Shelly Hayes MD","doi":"10.1016/j.adro.2025.101977","DOIUrl":"10.1016/j.adro.2025.101977","url":null,"abstract":"<div><h3>Purpose</h3><div>Men 80 and over are not well represented on randomized clinical trials, including the studies that examined the addition of androgen deprivation (ADT) to radiation therapy (RT). However, octogenarians may be a group particularly susceptible to the side effects of ADT due to the rapid increase in age-related changes as one enters their 9th decade. We hypothesized that ADT, when added to RT in octogenarians with intermediate-risk prostate cancer, might be associated with worse overall survival, and that this effect would not hold for their younger counterparts.</div></div><div><h3>Methods and Materials</h3><div>The National Cancer Database (NCDB) was queried for men ≥60 years old who received dose-escalated RT (EQD2_α/β=2 ≥ 74 Gy) for intermediate-risk prostate cancer. Intermediate risk was defined as prostate specific antigen (PSA) &gt; 10 and ≤ 20, Gleason score 7 (either 3+4 or 4+3), or T2 disease. Men were separated by age (60-69, 70-79, ≥80) and receipt of ADT. Overall survival was evaluated using Kaplan-Meier analysis. Cox proportional hazards were used to determine the relationship between ADT usage on survival in different age cohorts.</div></div><div><h3>Results</h3><div>There were 10,168 men who received RT + ADT versus 12,396 who received RT alone. In the RT + ADT group, a larger percentage of men had Gleason 4+3 disease (43% vs 26%, <em>P</em> = .004), T2 stage (35% vs 25%, <em>P</em> = .019), and a higher PSA (median 7.6 vs 6.8, <em>P</em> &lt; .0001). There were 672 (6.6%) octogenarians who received ADT versus 772 (6.2%) who did not. Hazard ratios (HRs) for overall survival, accounting for Gleason score, T stage, PSA, and comorbid conditions, showed improved survival in those 60 to 69 with the addition of ADT to dose-escalated RT (HR = 0.90 [95% CI, 0.81-0.99], <em>P</em> = .039), while no difference in those 70-79 (HR = 0.98 [0.90-1.06], <em>P</em> = .541) or 80 and older (HR = 1.13 [0.97-1.32], <em>P</em> = .124).</div></div><div><h3>Conclusions</h3><div>In this NCDB analysis, the addition of ADT to dose-escalated radiation in men between the ages of 60 and 70 with intermediate-risk prostate cancer showed improved overall survival. However, adding ADT to dose escalation in those 80 and older did not demonstrate an overall survival benefit.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 3","pages":"Article 101977"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Proton Therapy of a Pregnant Patient With Small-Cell Lung Cancer in the Third Trimester Using Synthetic Computed Tomographies for Tumor Monitoring","authors":"Gloria Vilches-Freixas PhD ,&nbsp;Mirko Unipan PhD ,&nbsp;Marije Velders BSc ,&nbsp;Menke Weessies MSc ,&nbsp;Esther Kneepkens PhD ,&nbsp;Ilaria Rinaldi PhD ,&nbsp;Vicki Trier Taasti PhD ,&nbsp;Michel Öllers PhD ,&nbsp;Mart Wubbels MSc ,&nbsp;Anna Sadowska MD, PhD ,&nbsp;Stijn van Teeffelen MD, PhD ,&nbsp;Stéphanie Peeters MD, PhD","doi":"10.1016/j.adro.2025.101972","DOIUrl":"10.1016/j.adro.2025.101972","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 4","pages":"Article 101972"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Findings in the Visualization of Subepithelial Melanoma or Pseudoprogression-Like Phenomena in Oral Mucosal Melanoma During Carbon-Ion Radiation Therapy","authors":"Hiroaki Ikawa DDS, PhD ,&nbsp;Masashi Koto MD, PhD ,&nbsp;Makoto Shinoto MD, PhD ,&nbsp;Hitoshi Ishikawa MD, PhD","doi":"10.1016/j.adro.2025.101976","DOIUrl":"10.1016/j.adro.2025.101976","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 3","pages":"Article 101976"},"PeriodicalIF":2.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}